Human primary mast cells as an advanced model for drug development
Chenyan Wu1, Anthony David1, Anne Dalapa-Amana1, Catherine Marques1, Alexandra Ochando2, Lorna Santos2 and Nicolas Gaudenzio3
1Genoskin SAS, Toulouse, France, 2Genoskin Inc, Salem MA, USA, 3Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 – CNRS UMR5051 – University Toulouse III, France
A reliable platform for assessing efficacy, toxicity, and safety
At the conference, we presented a scientific poster describing the development and validation of our standardized human primary mast cell platform for assessing drug-induced immune activation, hypersensitivity, and inflammatory responses in a human-relevant system.
The data demonstrated reproducible generation of mature mast cells expressing CD117, FcεRI, and MRGPRX2, along with consistent degranulation responses across donors following IgE- and MRGPRX2-mediated stimulation—supporting reliable, translational immune safety assessment in preclinical development.
Please fill in the form below to access the full poster.
After submitting this form, you will receive an email with the link to access our poster.
Want more research like this in your inbox? Subscribe to our newsletter →
Comments are closed.